

From Disruption to Opportunity

Embracing Change in Health Care

Sep 4 to 6



Shaw Centre,
Ottawa

PRELIMINARY PROGRAM (as of May 29, 2024)

WEDNESDAY, SEPTEMBER 4, 2024	
WORKSHOPS / SPECIAL SESSIONS / MEET AND GREETES / WELCOME RECEPTION	
8:00 a.m. to 7:30 p.m.	REGISTRATION DESK OPEN
7:30 a.m. to 8:30 a.m.	CONTINENTAL BREAKFAST
8:30 a.m. to 11:30 a.m.	WORKSHOP Qualitative Thinking and Best Practices in HTA: Unlocking Opportunities for Policy Impact Francesca Brundisini, Jamie Anne Bentz, and Elijah Herrington, Canada's Drug Agency
8:30 a.m. to 11:30 a.m.	WORKSHOP Innovative Approaches to Real-World Evidence Generation: Selecting the Appropriate Study Design to Answer Your Evidence Needs Calum Neish, IQVIA Solutions Canada Inc.
12:15 p.m. to 1:30 p.m.	SPECIAL SESSION A New Era of Innovation and Collaboration in PMDE Tarry Ahuja, Canada's Drug Agency
12:15 p.m. to 3:15 p.m.	WORKSHOP Unlocking Ethics in HTA: Exploring Practice and Impact Renata Axler and Ana Komparic, Canada's Drug Agency
12:15 p.m. to 3:15 p.m.	WORKSHOP Gauging HTA Topic Importance and Potential Impact to Clinical Providers and Health Systems Johanna Anderson, Erin Beech, and Nicolas Parr, US Department of Veterans Affairs
1:30 p.m. to 2:00 p.m.	NETWORKING BREAK
2:00 p.m. to 3:15 p.m.	SPECIAL SESSION Drugs for Rare Diseases Nicole Mittmann, Trish Caetano, Canada's Drug Agency

3:30 p.m. to 4:45 p.m.	SPECIAL SESSION Focus on Methods Farah Husein, Deirdre DeJean, and Renata Axler, Canada's Drug Agency
4:45 p.m. to 5:30 p.m.	STUDENT MEET AND GREET Students attending the Symposium in person are invited to meet other student attendees and senior staff from Canada's Drug Agency. A cash bar and light refreshments will be available.
4:45 p.m. to 5:30 p.m.	PATIENT GROUP MEET AND GREET Representatives of patient groups attending the Symposium in person are invited to meet one another and senior staff from Canada's Drug Agency.
5:15 p.m. to 7:00 p.m.	WELCOME RECEPTION AND SCIENTIFIC POSTER EXHIBITION The Welcome Reception features scientific posters and the opportunity to meet and talk with the authors about their work. Recipients of the 2024 Recognition Awards will be presented.

THURSDAY, SEPTEMBER 5, 2024	
EARLY MORNING SESSIONS / OFFICIAL OPENING / OPENING PLENARY / CONCURRENT SESSIONS / SOCIAL EVENT	
7:30 a.m. to 5:30 p.m.	REGISTRATION DESK OPEN
7:30 a.m. to 8:30 a.m.	BREAKFAST
7:45 a.m. to 8:30 a.m.	EARLY MORNING SESSION Operationalizing Outcomes-Based Agreements in Canada Kate Harback, Institute of Health Economics
7:45 a.m. to 8:30 a.m.	EARLY MORNING SESSION The Growing Problem of Drug Shortages: Understanding Their Impact on Research, Patients, and Healthcare Systems Mina Tadrous, University of Toronto; Stephanie Di Trapani, Health Canada; Saad Ahmed, University of Toronto
7:45 a.m. to 8:30 a.m.	EARLY MORNING SESSION Embracing Healthcare Evolution: Using a Discrete Event Simulation Approach to Enhance Kidney Allocation Strategies Shahzad Ghanbarian, University of British Columbia
8:45 a.m. to 9:30 a.m.	OFFICIAL OPENING Suzanne McGurn, President and CEO, Canada's Drug Agency
9:30 a.m. to 10:45 a.m.	OPENING PLENARY INTRODUCING CANADA'S DRUG AGENCY In December 2023, the Government of Canada announced that the Canadian Drug Agency would be built from CADTH in consultation with the provinces and territories. The work of the drug agency would expand upon CADTH's existing mandate to assess drugs and other health technologies and contribute to even stronger health care systems across the country. Bill C-64, the Pharmacare Act, was given First Reading in Parliament on February 29, 2024, outlining additional responsibilities for the Canadian Drug Agency. This plenary session will introduce this new drug agency, now named Canada's Drug Agency / l'Agence des médicaments du Canada (CDA-AMC), as well as the thinking leading up to the launch, the implications of Bill C-64, the agency's role going forward, and how it will fit within the overall drug management system in Canada. <ul style="list-style-type: none">• Suzanne McGurn, President and CEO, Canada's Drug Agency

	<ul style="list-style-type: none"> • Guillaume Couillard, Executive Director, Patented Medicine Prices Review Board • Michelle Boudreau, Associate Assistant Deputy Minister, Strategic Policy Branch, Health Canada • Patrick Dicerni, Assistant Deputy Minister Health Programs and Delivery Division and Executive Officer, Ontario Public Drug Programs, Ontario Ministry of Health and Long-Term Care
10:45 a.m. to 11:15 a.m.	NETWORKING BREAK
11:15 a.m. to 12:30 p.m.	PANEL SESSION Innovation in the Pharmaceutical Ecosystem Sudha Kutty and Peter Dyrda, Canada's Drug Agency
11:15 a.m. to 12:30 p.m.	PANEL SESSION Cultivating INDequity Through Indigenous-Led Pathways to eHealth Using an Innovative P3 Model to Partnership Vanessa Ambtman-Smith, Western University; Mehmood Alibhai, Boehringer Ingelheim Canada Ltd.
11:15 a.m. to 12:30 p.m.	PANEL SESSION Developing a Real-World Readiness Framework for Patient Support Programs: A Collaborative Approach Daniel Zimskind, ZS; Bryan Asher, Shoppers Drug Mart; Sarah Power, Takeda; Barry Stein, Colorectal Cancer Canada
11:15 a.m. to 12:30 p.m.	PANEL SESSION Incorporating the Child's Perspective in Health Technology Assessment in Canada Jessie Elliot, Canada's Drug Agency; Brittany Humphries, McMaster University; Wendy Ungar, Hospital for Sick Children Research Institute; Feng Xie, McMaster University
11:15 a.m. to 12:30 p.m.	PANEL SESSION Delivering Precision Oncology as Standard of Care: How Genomic Testing Is Driving Better Patient Outcomes and Increased Access to Clinical Trials for Cancer Patients Michael Carter and Tanya Gillian, Nova Scotia Health; Ravi Ramjeesingh, Dalhousie University
12:30 p.m. to 1:30 p.m.	NETWORKING LUNCH
1:30 p.m. to 2:45 p.m.	ORAL PRESENTATIONS RARE DISEASE REGISTRIES Building an Inventory of Rare Disease Registries in the Canadian Landscape Claudia Sikorski, Canada's Drug Agency Developing Registry Standards Farah Husein, Canada's Drug Agency Enhancing Data Quality and Infrastructure in Canadian Rare Disease Registries Viktoria Roman, Canada's Drug Agency
1:30 p.m. to 2:45 p.m.	ORAL PRESENTATIONS ONCOLOGY The Growing Importance of Companion Diagnostics on Cancer Therapeutics and Funding Scott Gavura, Ontario Health (Cancer Care Ontario) PROgress Tracker Breast Cancer Registry: Diverse Real-World Evidence to Inform HTA via a Patient Reported Outcomes Longitudinal Study of Canadian Breast Cancer Survivors Kimberly Carson and Shaniah Leduc, Breast Cancer Canada

	<p>Patient Values Project: Understanding Patient Preferences for Cancer Treatments to Inform a Framework for Incorporating Patient Values Into Health Technology Assessment Deborah A Marshall, University of Calgary</p>
1:30 p.m. to 2:45 p.m.	<p>ORAL PRESENTATIONS HOT TOPICS Partnering Together for Integrated Person- and Family-Centric Care Across the Mental Wellness Care Continuum: Stepped Care 2.0 in the Northwest Territories Danielle Impey, Mental Health Commission of Canada Navigating Growth: Ontario’s CAR T-Cell Therapy Program Cassandra McKay, Ontario Health (Cancer Care Ontario) Developing a Drug Shortages Predictive Model Using Real-World Canadian Drug Utilization Araniy Santhireswaran, University of Toronto Improving Equity Assessment in Drug Policy Decisions Jolanta Piszczek, University of British Columbia Therapeutic Value of Drugs for Orphan Diseases Joel Lexchin, York University</p>
1:30 p.m. to 2:45 p.m.	<p>ORAL PRESENTATIONS ARTIFICIAL INTELLIGENCE AND DIGITAL HEALTH Homecare Innovations: At the Intersection of Technology and Humanity Corelia Kostovic and Marie-Helene Raymond, INESSS A National Standard for Cyber Resiliency in Healthcare Siri Chunduri and Jonathan I. Mitchell, HealthCareCAN Clinical Practice in a Digital Health Environment: New Best Practice Guideline Lauren Bailey, Registered Nurses’ Association of Ontario (RNAO)</p>
2:45 p.m. to 3:15 p.m.	<p>NETWORKING BREAK</p>
3:15 p.m. to 4:30 p.m.	<p>PANEL SESSION Disruptive Partnership: Charting the Future of pan-Canadian Data and Analytics Elena Lungu, Canada’s Drug Agency</p>
3:15 p.m. to 4:30 p.m.	<p>PANEL SESSION Breaking Barriers: Tackling Challenges in Mental Health Drug Health Technology Assessments Matthew Dick, IQVIA Solutions Canada Inc. (moderator); Don Husereau, IHE; Roger McIntyre, University of Toronto</p>
3:15 p.m. to 4:30 p.m.	<p>PANEL SESSION Rethinking How We Do HTA: Toward a Broader Health System Approach Leslie Anne Campbell, Dalhousie University; Craig Mitton, UBC; Laura Weeks, Canada’s Drug Agency</p>
3:15 p.m. to 4:30 p.m.	<p>PANEL SESSION Advancing Patient Engagement and Impact in CADTH’s Deliberative Process: A Multistakeholder Collaboration William Dempster, 3Sixty Public Affairs (Moderator); Gail Attara, Gastrointestinal Society; Bonnie Macfarlane, Janssen Inc.; Heather Logan, Canada’s Drug Agency; Jessy Ranger, Myeloma Canada; Nancy Zorzi, Mood Disorders Society of Canada</p>
5:30 p.m. to 9:00 p.m.	<p>SOCIAL EVENT</p>

FRIDAY, SEPTEMBER 6, 2024	
EARLY MORNING SESSIONS / CONCURRENT SESSIONS / CLOSING PLENARY / CLOSING RECEPTION	
7:30 a.m. to 3:00 p.m.	REGISTRATION DESK OPEN
7:30 a.m. to 8:45 a.m.	BREAKFAST
7:45 a.m. to 8:30 a.m.	EARLY MORNING SESSION Real-World Evidence (RWE): Empowering Patient Advocacy Groups to Co-Design Registries That Fill a Data Gap for Their Community Kyle Fitzgerald, Alzheimer Society of Ontario, Christa Studzinski, Ontario Brain Institute
7:45 a.m. to 8:30 a.m.	EARLY MORNING SESSION Tackling Environmental Impacts in Healthcare Systems and in Health Technology Assessment Agencies Towards 2030: Where Do We Stand With 6 Years Left? Corelia Kostovic, INESSS
7:45 a.m. to 8:30 a.m.	EARLY MORNING SESSION What's New in US HTA? A Snapshot of ICER's Value Assessment Framework Update Daniel Ollendorf and Marina Richardson, Institute for Clinical and Economic Review (ICER)
8:45 a.m. to 10:00 a.m.	PANEL SESSION Closing the Gap or Widening the Divide: Do We Need a Framework for Truly Embedding Equity in Health Technology Assessment (HTA)? Jonathan Pearson-Stuttard, Lane Clark & Peacock LLP (Moderator), Stephen Duffield, National Institute for Health and Care Excellence; Susan Griffin, University of York; Chris Lubker, Novo Nordisk; Marina Richardson, Institute for Clinical and Economic Review
8:45 a.m. to 10:00 a.m.	PANEL SESSION Appropriate Use Sudha Kutty, Canada's Drug Agency
8:45 a.m. to 10:00 a.m.	PANEL SESSION An Innovative and Learning Health System Fueled by Digital and Technological Transformation: Recent Successes From the Nova Scotia Health Cancer Care Program Amanda Caissie, Helmut Hollenhorst, and Gail Tomblin Murphy, Nova Scotia Health
8:45 a.m. to 10:00 a.m.	PANEL SESSION From Disruption to Opportunity: What Can HTA Learn from Taylor Swift? Nancy Sikich, Sarah McDowell, Chunmei Li, and Olga Gajic-Veljanoski, Ontario Health
10:00 a.m. to 10:30 a.m.	NETWORKING BREAK
10:30 a.m. to 11:30 a.m.	ORAL PRESENTATIONS DIVERSE PERSPECTIVES Prioritizing Community Partnerships: A Collaborative Approach to Promoting Medication Appropriateness Across Diverse B.C. Communities Leslie Gaudette, Council of Senior Citizens' Organizations of British Columbia Advancing Justice-Oriented Patient Engagement in Health Technology Assessment Roma Dhamanaskar, McMaster University Public Preferences for Improving Health Equity in Canada: A Qualitative Focus Group Study Christopher Cadham, University of Michigan

10:30 a.m. to 11:30 a.m.	<p>ORAL PRESENTATIONS</p> <p>MAXIMIZING THE IMPACT OF HTA</p> <p>Improving the Impact of Health Technology Assessment (HTA) in Canada Craig Mitton, University of British Columbia</p> <p>An Actionable and Legible Toolbox for the Appraisal of Healthcare Innovations Developed Through Provincial Stakeholder Collaboration Pascale Lehoux, INESSS</p>
10:30 a.m. to 11:30 a.m.	<p>ORAL PRESENTATIONS</p> <p>HTA METHODS</p> <p>Quantitative Assessment of Effect Modifiers in NMA: Leveraging Subgroup Data Timothy Disher, CRG-EVERSANA</p> <p>Humanizing HTA Practices: The INESSS Users' and Relatives' Panel Louis Lochhead and Marie-Pascale Pomey, INESSS</p> <p>Understanding and Measuring Health Outcomes in Children With Rare Genetic Conditions Jeff Round, Institute of Health Economics</p>
10:30 a.m. to 11:30 a.m.	<p>ORAL PRESENTATIONS</p> <p>HEALTH ECONOMICS</p> <p>Model-Based Estimates of the Cost of Obstetric Evacuation for Fly-In First Nation Communities in Ontario Majd Radhaa, Western University</p> <p>Identifying High-Cost Users in Ontario: Implications of Follow-Up Time and Censoring for Measuring High-Cost Users Using Administrative Data Kali Barrett, University of Toronto</p> <p>Integrating Lived Experience: Developing a Theoretical and Methodological Approach to Conducting an Institutional Ethnography for Economic Evaluations Chantal Valiquette, University of Toronto</p> <p>23 and (Not Just) Me: Incorporating Family Members in Economic Evaluation of Genetic Testing Technologies Wendy Ungar, Technology Assessment at SickKids (TASK), Hospital for Sick Children Research Institute</p>
10:30 a.m. to 11:30 a.m.	<p>ORAL PRESENTATIONS</p> <p>MEDICAL DEVICES</p> <p>Level 2 Polysomnography for the Diagnosis of Sleep Disorders: A Health Technology Assessment Samrawit Lemma, Stacey Vandersluis, Nancy Sikich, Ontario Health (OH)</p> <p>The Canadian Medical Imaging Inventory (CMII): A Decade of Difference Andra Morrison, Canada's Drug Agency</p>
11:30 a.m. to 12:00 p.m.	<p>NETWORKING BREAK</p>
12:00 p.m. to 1:15 p.m.	<p>CLOSING PLENARY</p> <p>FROM DISRUPTION TO OPPORTUNITY: IMPLEMENTING AI AND OTHER INNOVATIONS</p> <p>An international panel of senior HTA leaders will share their insights and experiences on how HTA can effectively address disruptive innovations, such as artificial intelligence (AI), to create opportunities for improved patient outcomes and cost-effective health care delivery. They'll discuss why disruptive innovation is needed, the potential risks and benefits of AI and other innovative technologies, and what jurisdictions around the world are doing to adapt to these new challenges. Attendees will gain valuable insights into the role of HTA in embracing change and driving innovation in health care. They will leave with a deeper understanding of how HTA can</p>

	<p>help health care systems adapt to disruptions, seize opportunities, and ultimately improve patient outcomes and the sustainability of health care delivery.</p> <ul style="list-style-type: none"> • Sudha Kutty, Executive Vice-President, Evidence, Products, and Services, Canada's Drug Agency (moderator) • Nick Crabb, Programme Director, Scientific Affairs, National Institute for Health and Care Excellence (NICE) • Pascale Lehoux, Vice-Présidente Scientifique, INESSS • Nicole Mittmann, Chief Scientist and Vice-President, Scientific Evidence, Methodologies and Resources, Canada's Drug Agency • Dan Ollendorf, Chief Scientific Officer and Director of HTA Methods Development, Institute for Clinical and Economic Review (ICER)
1:15 p.m. to 1:30 p.m.	<p>PRESENTATION OF THE STUDENT POSTER AWARD AND OFFICIAL CLOSING Suzanne McGurn, President and CEO, Canada's Drug Agency</p>
1:30 p.m. to 2:30 p.m.	<p>CLOSING RECEPTION Join us for the grand finale of Symposium 2024 at the closing reception! Unwind and network with fellow attendees. Celebrate the culmination of insightful discussions and fruitful connections in a relaxed and inviting atmosphere. Don't miss this opportunity to toast the success of another memorable Symposium experience! Delectable appetizers and a cash bar will be available.</p>